Acyclovir
- Generic Name
- Acyclovir
- Brand Names
- Sitavig, Xerese, Zovirax
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N5O3
- CAS Number
- 59277-89-3
- Unique Ingredient Identifier
- X4HES1O11F
- Background
Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.
Acyclovir was granted FDA approval on 29 March 1982.
- Indication
An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients. An acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older. An acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialis. An acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitis.
- Associated Conditions
- Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes
Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis
- Conditions
- Herpetic Keratitis
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 20
- Registration Number
- NCT06757907
- Locations
- 🇪🇬
Al-Azhar university, Damietta, Egypt
Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- King Edward Medical University
- Target Recruit Count
- 64
- Registration Number
- NCT06380647
- Locations
- 🇵🇰
department of pediatric surgery King Edward Medical University, Lahore, Punjab, Pakistan
Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial.
- Conditions
- Plantar Wart
- Interventions
- Device: Cryotherapy
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 92
- Registration Number
- NCT06261684
- Locations
- 🇪🇬
Cairo University Hospital, Cairo, Egypt
The Bioequivalence Study of Acyclovir 800 mg Tablet in Healthy Thai Volunteers Under Fasting Conditions
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Zovirax™ 800 mg Tablet
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- International Bio service
- Target Recruit Count
- 40
- Registration Number
- NCT06228430
Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes (PTH2)
- Conditions
- Invasive Mechanical VentilationHSV Throat Reactivation
- Interventions
- Drug: Saline bags
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 246
- Registration Number
- NCT06217406
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
- Conditions
- Ventilator Associated PneumoniaHospital-acquired PneumoniaCommunity-acquired PneumoniaHerpes SimplexPneumonia, Viral
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Jena University Hospital
- Target Recruit Count
- 616
- Registration Number
- NCT06134492
- Locations
- 🇩🇪
Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
🇩🇪Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany
🇩🇪Universitätsklinikum Augsburg, Augsburg, Bayern, Germany
Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 20
- Registration Number
- NCT05589688
- Locations
- 🇫🇷
Toulouse Hospital, Toulouse, France
Aciclovir Versus Placebo for HSV-2 Meningitis
- Conditions
- Herpes Simplex 2Meningitis, Viral
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Jacob Bodilsen
- Target Recruit Count
- 150
- Registration Number
- NCT05452928
Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts
- Conditions
- Acyclovir and Candida Antigen in Treatment of Plantar Wart
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 40
- Registration Number
- NCT05429151
- Locations
- 🇪🇬
Sohag, Sohag, Egypt
Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 44
- Registration Number
- NCT05324904
- Locations
- 🇪🇬
Assuit University, Assiut, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.